Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The recently published LEADER study demonstrates the potential of these drugs to reduce CV risk in patients with T2DM, but whether such benefits extend to patients with CKD needs to be explored.(51) Similarly, the EMPA-REG OUTCOME trial has demonstrated that empagliflozin, a SGLT2 inhibitor, was associated with slower…”
BackgroundBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationRomagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.88 · Cited by 996
Self-citationHeerspink, H. J. L., Parving, H.-H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F.-F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30772-x · Cited by 628
Self-citationHeerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Floege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
“Indepth collaboration among pathologists, pharmacists, nurses, and clinicians is essential.(54) Accelerating new drug development coupled with more sophisticated and efficient treatment trials is critical to improving success.”
BackgroundMethodSelf-citationJiang, G., Luk, A. O. Y., Tam, C. H. T., Xie, F., Carstensen, B., Lau, E. S. H., Lim, C. K. P., Lee, H. M., Ng, A. C. W., Ng, M. C. Y., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.08.026 · Cited by 159
Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury
Hung, A. M., Siew, E. D., Wilson, O. D., Perkins, A. M., Greevy, R. A., Horner, J., Abdel-Kader, K., Parr, S. K., Roumie, C. L., Griffin, M. R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1237 · Cited by 49
Self-citationCollard, D., Brouwer, T. F., Peters, R. J. G., Vogt, L., & van den Born, B.-J. H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11944 · Cited by 30
Metadata
- Authors
- Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., Bakris, G. L., Cooper, M. E., Chae, D.-W., Davidson, M. H., de Boer, I. H., de Zeeuw, D., Fornoni, A., Gnudi, L., Herzog, C. A., Hung, A. M., Jafar, T. H., Jardine, M., Jha, V., Ji, L., Kahn, S. E., Langham, R. G., Lerma, E. V., Ma, R. C. W., Makino, H., Marre, M., Mauer, M., Metsärinne, K., Nelson, R. G., Pecoits-Filho, R., Pollock, C. A., Rajapurkar, M., Rossing, P., Rychlík, I., Sharma, K., Stanton, R. C., Tesař, V., Tikkanen, I., Tomson, C. R. V., Toto, R. D., Tsukamoto, Y., Tuttle, K. R., Wada, T., Williams, W. W., Zhang, H., & Zoungas, S.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 90
- Issue
- 6
- Pages
- 1175-1183
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2552060437
- Cited by
- 136
- References
- 41
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.